...
首页> 外文期刊>Molecular cancer therapeutics >Modeling Therapy Response and Spatial Tissue Distribution of Erlotinib in Pancreatic Cancer
【24h】

Modeling Therapy Response and Spatial Tissue Distribution of Erlotinib in Pancreatic Cancer

机译:厄洛替尼在胰腺癌中的治疗反应和空间组织分布建模

获取原文
获取原文并翻译 | 示例
           

摘要

Pancreatic ductal adenocarcinoma (PDAC) is likely the most aggressive and therapy-resistant of all cancers. The aim of this study was to investigate the emerging technology of matrix-assisted laser desorption/ionization imaging mass spectrometry (MALDI IMS) as a powerful tool to study drug delivery and spatial tissue distribution in PDAC. We utilized an established genetically engineered mouse model of spontaneous PDAC to examine the distribution of the small-molecule inhibitor erlotinib in healthy pancreas and PDAC. MALDI IMS was utilized on sections of single-dose or long-term-treated mice to measure drug tissue distribution. Histologic and statistical analyses were performed to correlate morphology, drug distribution, and survival. We found that erlotinib levels were significantly lower in PDAC compared with healthy tissue (P = 0.0078). Survival of long-term-treated mice did not correlate with overall levels of erlotinib or with overall histologic tumor grade but did correlate both with the percentage of atypical glands in the cancer (P = 0.021, r(s) = 0.59) and the level of erlotinib in those atypical glands (P = 0.019, r(s) = 0.60). The results of this pilot study present MALDI IMS as a reliable technology to study drug delivery and spatial distribution of compounds in a preclinical setting and support drug imaging-based translational approaches. (C) 2016 AACR.
机译:胰腺导管腺癌(PDAC)可能是所有癌症中最具攻击性和治疗抵抗力的。这项研究的目的是研究新兴的基质辅助激光解吸/电离成像质谱(MALDI IMS)技术,作为研究PDAC中药物输送和空间组织分布的强大工具。我们利用已建立的自发PDAC的基因工程小鼠模型来检查小分子抑制剂厄洛替尼在健康胰腺和PDAC中的分布。 MALDI IMS用于单剂量或长期治疗小鼠的切片,以测量药物组织的分布。进行组织学和统计分析以关联形态,药物分布和生存。我们发现与健康组织相比,PDAC中的厄洛替尼水平显着降低(P = 0.0078)。长期治疗的小鼠的存活率与厄洛替尼的总体水平或组织学总体分级无关,但与癌症中非典型腺体的百分比均相关(P = 0.021,r(s)= 0.59)和该水平非典型腺体中厄洛替尼的使用率(P = 0.019,r(s)= 0.60)。这项初步研究的结果表明,MALDI IMS是一种可靠的技术,可以在临床前研究药物的递送和空间分布情况,并支持基于药物成像的翻译方法。 (C)2016 AACR。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号